IMproving PAtient UndeRstanding of GEP TEst Results: Phase 4

The primary aim of the study is to determine if provision of a patient information film about Oncotype DX improves patients' knowledge and understanding about Gene Expression Profiling (GEP) test and risk of recurrence results in early breast cancer (EBC) patients, identified by their clinical teams as potentially benefiting from having their tumor samples sent for GEP analysis.

Trial Details

NCT ID
NCT06703567
Phase
NA
Sponsor
European Institute of Oncology
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Standard Policy
  • Standard Policy + GEP Information Film
Locations (sample)
  • Milan, Italy|45.46427,9.18951

Key Eligibility Criteria

  • First presentation of early stage breast cancer with all known disease surgically removed
  • Estrogen Receptor (ER) positive and Human Epidermal growth factor Receptor 2 (HER-2) negative
  • No clear decision on whether chemotherapy should be given as adjunct based on current prognostic criteria
  • Consented to GEP testing

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →